These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19055988)

  • 1. The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
    Cairns JA; Eikelboom J
    J Am Coll Cardiol; 2008 Dec; 52(24):1978-80. PubMed ID: 19055988
    [No Abstract]   [Full Text] [Related]  

  • 2. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
    Erlinge D; Varenhorst C; Braun OO; James S; Winters KJ; Jakubowski JA; Brandt JT; Sugidachi A; Siegbahn A; Wallentin L
    J Am Coll Cardiol; 2008 Dec; 52(24):1968-77. PubMed ID: 19055987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
    Tapp L; Shantsila E; Lip GY
    Circulation; 2010 Mar; 121(10):1169-71. PubMed ID: 20194888
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antiplatelet agents for cardiovascular disease.
    Chua D; Nishi C
    CMAJ; 2013 Nov; 185(16):1405-11. PubMed ID: 24016786
    [No Abstract]   [Full Text] [Related]  

  • 6. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
    O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
    Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.
    Bernlochner I; Mayer K; Morath T; Orban M; Schulz S; Schömig A; Braun S; Kastrati A; Sibbing D
    Thromb Haemost; 2013 Mar; 109(3):517-24. PubMed ID: 23328965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet inhibition with prasugrel].
    Gassanov N; Caglayan E; Nia AM; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Aug; 135(31-32):1542-6. PubMed ID: 20665417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenoreceptors, platelet reactivity and clopidogrel resistance.
    Xiang YZ
    Thromb Haemost; 2008 Nov; 100(5):729-30. PubMed ID: 18989508
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Yokoi H; Kimura T; Isshiki T; Ogawa H; Ikeda Y
    Thromb Res; 2012 May; 129(5):623-8. PubMed ID: 22178576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensifying platelet inhibition--navigating between Scylla and Charybdis.
    Bhatt DL
    N Engl J Med; 2007 Nov; 357(20):2078-81. PubMed ID: 17982183
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
    Erlinge D; Ten Berg J; Foley D; Angiolillo DJ; Wagner H; Brown PB; Zhou C; Luo J; Jakubowski JA; Moser B; Small DS; Bergmeijer T; James S; Winters KJ
    J Am Coll Cardiol; 2012 Nov; 60(20):2032-40. PubMed ID: 23083774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ischaemia versus bleeding: the art of clinical decision-making.
    Stone GW
    Lancet; 2009 Feb; 373(9665):695-6. PubMed ID: 19249613
    [No Abstract]   [Full Text] [Related]  

  • 16. Test before you stop.
    Kumar A; Roberts DH
    Arch Surg; 2009 Aug; 144(8):787; author reply 787. PubMed ID: 19687387
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
    Tantry US; Jeong YH; Navarese EP; Kubica J; Gurbel PA
    Expert Rev Cardiovasc Ther; 2013 Apr; 11(4):447-62. PubMed ID: 23570358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Another view on prasugrel.
    Calatzis A
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.